Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fulcrum Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Form 8-K reports cover operating results, financial condition, Regulation FD corporate presentations, clinical updates for pociredir in sickle cell disease, and material agreements, including license arrangements tied to development programs.
Proxy materials disclose board and governance matters, executive compensation, equity awards, shareholder voting items, and related ownership information. The filing record also documents capital-structure items such as common stock and inducement equity plans alongside public-company disclosures tied to drug development programs and collaboration agreements.
Fulcrum Therapeutics, Inc. reported an executive leadership change in its finance organization. Vice President, Finance and principal accounting officer Greg Tourangeau, whose planned departure had been previously disclosed, will end his tenure on August 7, 2026. Effective the same date, the Board appointed chief financial officer and principal financial officer Alan Musso to also serve as principal accounting officer.
Musso’s background is described in the company’s definitive proxy statement filed on April 30, 2026. He will not receive additional compensation for assuming the principal accounting officer role. The company states there is no arrangement or understanding with any person regarding his appointment, no family relationships with other directors or executive officers, and no related-party transactions involving Musso that require disclosure under Item 404(a) of Regulation S-K.
Bank of America Corporation, through certain wholly owned subsidiaries, reports beneficial ownership of common stock of Fulcrum Therapeutics, Inc..
The group holds 4,468,123 shares of Fulcrum Therapeutics common stock, representing 6.7% of the outstanding class, based on 66,633,321 shares outstanding as reported by Fulcrum Therapeutics in its Form 10-Q for share totals as of April 20, 2026. All reported shares are held with shared voting and shared dispositive power; Bank of America and its reporting subsidiaries have no sole voting or dispositive power over these shares. The filing is made jointly on behalf of Bank of America Corporation and its wholly owned subsidiaries BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International.
Fulcrum Therapeutics, a rare‑disease drug developer, reported continued losses while fundamentally reshaping the business. After end‑of‑phase FDA feedback raised concerns about pociredir’s benefit‑risk profile in sickle cell disease, the company discontinued the program, ceased all research and development activities, and cut its workforce by about 85% from 57 to nine employees. Management is now conducting a comprehensive review of strategic alternatives, including a merger, acquisition, asset sale or licensing transaction, with Leerink Partners advising.
For the six months ended June 30, 2026, Fulcrum recorded a net loss of $45.1 million, compared with $35.0 million a year earlier, including $5.1 million of long‑lived asset impairments and $4.3 million of restructuring charges. Cash used in operations was $34.8 million. The company ended June with $318.8 million in cash, cash equivalents and marketable securities and an accumulated deficit of $639.3 million, and believes this liquidity will fund operating and capital needs for at least 12 months while it pursues potential transactions.
BlackRock, Inc. filed Amendment No. 4 reporting its beneficial ownership of common stock of THERAPEUTICS INC (symbol FULC). BlackRock reports beneficial ownership of 4,802,880 shares of common stock, representing 7.2% of the class.
BlackRock has sole voting powersole dispositive power
Kevin Tang and affiliated Tang Capital entities, as 10% owners of Fulcrum Therapeutics, reported indirect open-market purchases totaling 167,616 shares of common stock on July 16–17, 2026. Reported weighted-average prices were $3.56 and $3.52 per share, with trade ranges from $3.46 to $3.60. These shares are held through Tang Capital funds, and the trades were not reported under a Rule 10b5-1 trading plan.
BlackRock Portfolio Management LLC reported a passive ownership stake in THERAPEUTICS INC common stock on a Schedule 13G. The firm disclosed beneficial ownership of 4,021,379 shares, representing 6.0% of the outstanding common stock as of June 30, 2026.
BlackRock Portfolio Management LLC has sole voting power over 3,604,410 shares and sole dispositive power over 4,021,379 shares, with no shared voting or dispositive power. The shares are held on behalf of various underlying persons who may receive dividends or sale proceeds; according to the disclosure, no single such person holds more than five percent of the issuer’s outstanding common shares.
Tang Capital Management, LLC and related investment entities report beneficial ownership of 6,913,329 shares of Fulcrum Therapeutics, Inc. common stock, representing 10.4% of the class based on 66,633,321 shares outstanding as of April 20, 2026. All reported shares are held with shared voting and dispositive power, with no sole voting or dispositive authority for any filer.
Within this aggregate position, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc. respectively report shared power over 1,630,142, 2,160,423, 1,630,127 and 1,492,637 shares, all under the oversight of Kevin Tang.
Investment entities associated with Kevin Tang and Tang Capital Management LLC, each a ten percent owner of Fulcrum Therapeutics, Inc., reported open-market purchases of 249,946 shares of common stock from July 13–15, 2026 at prices ranging from $3.50 to $3.60 per share. Reported prices are weighted averages for multiple trades within these ranges.
Following these transactions, the reporting group’s indirect beneficial ownership increased to 6,913,329 shares, held across Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc., in which Kevin Tang has a pecuniary interest.
Fulcrum Therapeutics, Inc. reports that investment funds affiliated with Tang Capital beneficially own 6,663,383 shares of common stock, held indirectly. Kevin Tang and Tang Capital Management LLC are each identified as ten percent owners, with Kevin Tang having a pecuniary interest through several Tang Capital entities.
Fulcrum Therapeutics director Sonja Banks received a new stock option grant. The award covers 32,000 shares of common stock at an exercise price of $3.66 per share and expires on June 29, 2036. All shares are scheduled to vest on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after the grant date, subject to continued service.